Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years. J of Skin 2023, 7 (2), s150. https://doi.org/10.25251/skin.7.supp.150.